Article ACC26S2
Author(s): Gwang-Yee Jessica Hu, PharmD, BCCCP, Niti Shah, PharmD, BCCCP
Contact Hours 1.00
CERP A 1.00
Pharmacology Hours 0.75
Expires Feb 16, 2029
Required reading for all learners: Implicit Bias impacts patient outcomes
There are currently 6 SGLT2 inhibitor medications approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus, the reduction of cardiovascular disease risk and chronic kidney disease progression, and the treatment of heart failure. Information regarding dosing and indications for each agent including sotagliflozin, the only nonselective SGLT1 and SGLT2 inhibitor on the market is included in this article. Common warnings and significant adverse reactions associated with SGLT2 inhibitor use include genitourinary fungal and bacterial infections, necrotizing fasciitis and lower limb amputations, and ketoacidosis are also discussed.Learners must complete the entire activity and the associated evaluation AND read Implicit Bias impacts patient outcomes. No partial credit will be awarded.
AccreditationAmerican Association of Critical-Care Nurses is accredited as a provider of
nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for
{contactHours} contact hours.
The Nurse Planner has determined that no individuals with the ability to control content of this activity have relevant relationships with ineligible companies.
Activities with pharmacotherapeutic credit are to assist the APRN in fulfilling their education requirements for licensure and certification renewals.
Refund PolicyContinuing Education Activities are nonrefundable.